ScripMerck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte
Pink SheetEisai and Eli Lilly are to appeal against today’s final decision by England’s health technology assessment institute, NICE, to deny funding for their respective Alzheimer’s disease drugs – Leqembi and
ScripPresident Donald Trump is repeating his threats of tariffs on the pharmaceutical industry and pressurizing companies to bring more manufacturing back to the US and while Ireland would be, on paper
ScripEli Lilly and Verve Therapeutics agreed to a buyout on June 17 valued at approximately $1bn with a contingent value right (CVR) that could be attainable, bringing the total deal value to around $1.3bn